Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Briani, C.
Right arrow Articles by Doria, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Briani, C.
Right arrow Articles by Doria, A.
Related Collections
Right arrow All Immunology
Right arrow Autoimmune diseases
Right arrow Lupus
Right arrow Peripheral neuropathy
NEUROLOGY 2004;62:2288-2290
© 2004 American Academy of Neurology
Brief Communications

Thalidomide neurotoxicity

Prospective study in patients with lupus erythematosus

C. Briani, MD, G. Zara, MD, R. Rondinone, MD, S. Della Libera, MD, M. Ermani, MD, S. Ruggero, PhD, A. Ghirardello, PhD, S. Zampieri, PhD and A. Doria, MD

From the Department of Neurosciences (Drs. Briani, Zara, Ermani, and Ruggero), Department of Medical and Surgical Sciences (Drs. Rondinone, Della Libera, Ghirardello, Zampieri, and Doria), Rheumatology Division, University of Padova, Italy.

Address correspondence and reprint requests to Dr. Chiara Briani, Department of Neurosciences, University of Padova, Via Giustiniani, 5, 35128 Padova, Italy; e-mail: chiara.briani{at}unipd.it

The authors prospectively followed 14 patients treated with thalidomide for cutaneous lupus erythematosus (CLE), in order to evaluate the occurrence of peripheral neuropathy (PN) and to assess whether PN correlates with thalidomide dose. The patients were followed for up to 24 months with neurologic and electrophysiologic evaluations. Seven patients (50%) developed sensory axonal PN. The median time free from PN was 14 months. PN occurred after 10 months in the majority of patients. No correlations were found between thalidomide cumulative dose and occurrence of PN (Mann-Whitney U test; p > 0.16).

Received December 17, 2003. Accepted in final form February 17, 2004.

See also pages 2158 and 2291




This article has been cited by other articles:


Home page
 J. Neurol. Neurosurg. PsychiatryHome page
G Zara, M Ermani, R Rondinone, S Arienti, and A Doria
Thalidomide and sensory neurotoxicity: a neurophysiological study
J. Neurol. Neurosurg. Psychiatry, November 1, 2008; 79(11): 1258 - 1261.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Pharmacy PracticeHome page
J. R. Murillo Jr, J. E. Cox, and M. S. Oholendt
An Overview of Chemotherapy-Induced Peripheral Neuropathy
Journal of Pharmacy Practice, April 1, 2008; 21(2): 138 - 145.
[Abstract] [PDF]

Home page
 NeurologyHome page
R. Plasmati, F. Pastorelli, M. Cavo, E. Petracci, E. Zamagni, P. Tosi, D. Cangini, P. Tacchetti, F. Salvi, I. Bartolomei, et al.
Neuropathy in multiple myeloma treated with thalidomide: A prospective study
Neurology, August 7, 2007; 69(6): 573 - 581.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. Mileshkin, R. Stark, B. Day, J. F. Seymour, J. B. Zeldis, and H. M. Prince
Development of Neuropathy in Patients With Myeloma Treated With Thalidomide: Patterns of Occurrence and the Role of Electrophysiologic Monitoring
J. Clin. Oncol., September 20, 2006; 24(27): 4507 - 4514.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
S Zampieri, M Alaibac, L Iaccarino, R Rondinone, A Ghirardello, P Sarzi-Puttini, A Doria, and A Peserico
Tumour necrosis factor {alpha} is expressed in refractory skin lesions from patients with subacute cutaneous lupus erythematosus
Ann Rheum Dis, April 1, 2006; 65(4): 545 - 548.
[Abstract] [Full Text] [PDF]

Home page
 JWatch NeurologyHome page
Thalidomide Neuropathy: Does Dose Matter?
Journal Watch Neurology, January 14, 2005; 2005(114): 8 - 8.
[Full Text]

Home page
 NeurologyHome page
S. C. Apfel and D. W. Zochodne
Thalidomide neuropathy: Too much or too long?
Neurology, June 22, 2004; 62(12): 2158 - 2159.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by AAN Enterprises, Inc.